

2021-22 TEAM TRAVEL POLICY

TEAM TRAVEL

We are excited to start having Team Travel again! In order for Team Travel to occur safely, JHSC needs to follow a robust Covid testing process with a clear understanding of what happens if there are new symptoms, lost test results, or positive test results. Athletes & Staff that participate in Team Travel need to:

- Be U14 and older
- Be fully vaccinated*
- Follow testing protocols for each trip (pre/during/post)
- Understand that their individual plans will change if they exhibit new Covid-19 symptoms, have lost test results or have a positive test result.

TESTING PROTOCOLS

Athletes & Staff need to follow the Team Travel & Covid-19 Testing protocol specific to each trip, please reach out to your specific Program Director for more information. Typically, Athletes & Staff will test 3 days prior to a trip's departure and should test immediately post-trip. Depending on the duration of the trip, mid-trip testing may also be required. Athletes & Staff can only participate in Team Travel with proof of a negative test. *Testing protocols are still required if you are fully vaccinated.*

***CDC DEFINITIONS**

According to the [CDC](#) - people are considered **fully vaccinated** when: ±

- 2 weeks after their second dose in a 2-dose series, such as the Pfizer or Moderna vaccines, or
- 2 weeks after a single-dose vaccine, such as Johnson & Johnson's Janssen vaccine

If you don't meet these requirements, regardless of your age, you are **NOT** fully vaccinated.

JHSC believes that the health and safety of our athletes and staff is the highest priority; JHSC prefers to be conservative in regards to COVID-19.

EXHIBITING COVID-19 SYMPTOMS

Athletes & Staff that have exhibited symptoms should stay home and take a Covid-19 test. You may return to training after you have received a negative Covid-19 test result AND are symptom-free (without medication.)

JHSC is looking to the [CDC](#) and [Teton County Public Health](#) for guidance on policies and protocols that pertain to Covid-19. This is an evolving situation and it may be necessary to make changes to this policy.

± This guidance applies to COVID-19 vaccines currently approved or authorized for emergency use by the U.S. Food and Drug Administration (Pfizer-BioNTech, Moderna, and Johnson & Johnson [J&J]/Janssen COVID-19 vaccines) and some vaccines used for U.S. participants in COVID-19 vaccine trials (such as Novavax). This guidance can also be applied to COVID-19 vaccines that have been listed for emergency use by the World Health Organization (such as AstraZeneca/Oxford). More information is available at [Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC](#).

